Predicting the mechanism of phospholipidosis

Area of Science:

• Pharmacology
• Computational Chemistry
• Biochemistry

Background:

• The precise mechanisms underlying drug-induced phospholipidosis remain poorly understood.
• Proposed mechanisms include direct inhibition of phospholipid breakdown or drug binding to phospholipids, hindering degradation.

Purpose of the Study:

• To develop a predictive model for identifying drug targets associated with phospholipidosis.
• To elucidate the specific molecular mechanisms driving phospholipidosis induction by different drug classes.

Main Methods:

• Utilized the Parzen-Rosenblatt Window approach on the ChEMBL dataset to build a predictive model.
• Analyzed a dataset of 182 compounds to predict off-target activities related to phospholipidosis.
• Linked predicted off-target interactions to potential mechanisms of phospholipid accumulation.

Main Results:

• Phospholipidosis induction appears to involve distinct mechanisms depending on the causative cationic amphiphilic drug.
• Inhibition of phospholipase activity and enhanced cholesterol biosynthesis are identified as key contributing mechanisms.
• Four specific protein targets were implicated: sphingomyelin phosphodiesterase, phospholipase A2, lysosomal phospholipase A1, and lanosterol synthase.

Conclusions:

• Drug-induced phospholipidosis is mediated by multiple pathways, including phospholipase inhibition and altered cholesterol biosynthesis.
• Specific protein targets like sphingomyelin phosphodiesterase, phospholipases A1/A2, and lanosterol synthase are linked to these mechanisms.
• The findings provide a foundation for further experimental validation of these hypotheses.